Attention Deficit Hyperactivity Disorder (ADHD)
ADHD: Attention Deficit Hyperactivity Disorder
Resources
Basic InformationMore InformationTestsLatest NewsQuestions and AnswersBlog EntriesVideosLinksBook ReviewsSelf-Help Groups
Community

Talk about this issue in our mental health support community

Therapist Search
Find a Therapist:
 (USA/CAN only)

Use our Advanced Search to locate a therapist outside of North America.

Related Topics

Bipolar Disorder
Child & Adolescent Development Overview
Learning Disorders
View the Depression Primer - an illustrated book about Depression
Child Development and Parenting: Infants
Child Development and Parenting: Early Childhood

Intuniv Approved for Pediatric ADHD

(HealthDay News)
by -- Scott Roberts
Updated: Sep 3rd 2009

 

THURSDAY, Sept. 3 (HealthDay News) -- Intuniv (guanfacine) has been approved by the U.S. Food and Drug Administration to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in people aged 6 to 17, drug maker Shire Plc said Thursday.

The once-daily drug, to be available in 1-to-4 mg. strengths, is expected on pharmacy shelves in November, the company said in a news release. The way it works is unclear, but the drug is thought to directly engage receptors in the brain's prefrontal cortex, an area that has been linked to the disorder.

Intuniv is not a controlled substance and "has no known potential for abuse or dependence," Shire said. It cited statistics from the U.S. Centers for Disease Control and Prevention (CDC) that some 4.4 million children in the United States have been diagnosed with ADHD.

In clinical testing, the most common adverse reactions to Intuniv included tiredness, abdominal pain, dizziness, a drop in blood pressure, dry mouth and constipation, the company said.

More information

The CDC has more about ADHD.

Follow us on Twitter!

Find us on Facebook!





powered by centersite dot net